Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Apr;66(4):436–441. doi: 10.1136/jnnp.66.4.436

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study

M Pinter 1, O Pogarell 1, W Oertel 1
PMCID: PMC1736320  PMID: 10201413

Abstract

OBJECTIVES—Pramipexole, a non-ergot dopamine D2/D3 receptor agonist, was investigated as an add on drug in advanced parkinsonian patients with motor fluctuations to assess efficacy, safety, and tolerance.
METHODS—Seventy eight patients of either sex with advanced Parkinson's disease and treatment complications such as motor fluctuations were enrolled into a double blind, placebo controlled, randomised, multicentre study (phase II) and assigned to add on treatment with pramipexole (n=34) versus placebo (n=44) to a previously stabilised antiparkinsonian medication (7 week dose titration interval, 4 week maintenance period). The primary end point of efficacy was the change from baseline in the total score of the unified Parkinson's disease rating scale (UPDRS) in the on "period" (2 hours after intake of study medication). Safety and tolerability were assessed on the basis of adverse events, vital signs, laboratory measurements, and ECG recordings.
RESULTS—There was a significant improvement of the pramipexole group in UPDRS total scores, subscores part II, III (activities of daily living and motor examination), and IV (complications of therapy). Mean UPDRS total score decreased by 37.3% under pramipexole compared with 12.2% under placebo (p<0.001). Patients under pramipexole reported an overall reduction in "off" periods of 12%—resulting in 1.7 more hours "on" time a day—compared with an increase in "off" periods of 2% under placebo. There were no unexpected safety results. The adverse event profile disclosed a high tolerability. The most important adverse events under pramipexole were fatigue, dyskinesia, and vivid dreams.
CONCLUSION—Pramipexole administration is an efficacious and well tolerated add on therapy in patients with advanced Parkinson's disease with an improvement in activities of daily living, motor function, and treatment associated complications.



Full Text

The Full Text of this article is available as a PDF (128.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Demonet J. F., Rostin M., Dueymes J. M., Ioualalen A., Montastruc J. L., Rascol A. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol. 1986;9(2):200–201. doi: 10.1097/00002826-198604000-00012. [DOI] [PubMed] [Google Scholar]
  2. Eisler T., Hall R. P., Kalavar K. A., Calne D. B. Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology. 1981 Oct;31(10):1368–1370. doi: 10.1212/wnl.31.10.1368. [DOI] [PubMed] [Google Scholar]
  3. Gibb W. R., Lees A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745–752. doi: 10.1136/jnnp.51.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997 Oct;49(4):1060–1065. doi: 10.1212/wnl.49.4.1060. [DOI] [PubMed] [Google Scholar]
  5. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  6. Hubble J. P., Koller W. C., Cutler N. R., Sramek J. J., Friedman J., Goetz C., Ranhosky A., Korts D., Elvin A. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol. 1995 Aug;18(4):338–347. doi: 10.1097/00002826-199508000-00006. [DOI] [PubMed] [Google Scholar]
  7. Kreiss D. S., Bergstrom D. A., Gonzalez A. M., Huang K. X., Sibley D. R., Walters J. R. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol. 1995 Apr 24;277(2-3):209–214. doi: 10.1016/0014-2999(95)00069-w. [DOI] [PubMed] [Google Scholar]
  8. Lieberman A., Ranhosky A., Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997 Jul;49(1):162–168. doi: 10.1212/wnl.49.1.162. [DOI] [PubMed] [Google Scholar]
  9. Melmed S., Braunstein G. D. Bromocriptine and pleuropulmonary disease. Arch Intern Med. 1989 Feb;149(2):258–259. [PubMed] [Google Scholar]
  10. Mierau J., Schneider F. J., Ensinger H. A., Chio C. L., Lajiness M. E., Huff R. M. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995 Jun 23;290(1):29–36. doi: 10.1016/0922-4106(95)90013-6. [DOI] [PubMed] [Google Scholar]
  11. Molho E. S., Factor S. A., Weiner W. J., Sanchez-Ramos J. R., Singer C., Shulman L., Brown D., Sheldon C. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl. 1995;45:225–230. [PubMed] [Google Scholar]
  12. Robertson G. S., Tham C. S., Wilson C., Jakubovic A., Fibiger H. C. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther. 1993 Mar;264(3):1344–1351. [PubMed] [Google Scholar]
  13. Shannon K. M., Bennett J. P., Jr, Friedman J. H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology. 1997 Sep;49(3):724–728. doi: 10.1212/wnl.49.3.724. [DOI] [PubMed] [Google Scholar]
  14. Wright C. E., Sisson T. L., Ichhpurani A. K., Peters G. R. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 1997 Jun;37(6):520–525. doi: 10.1002/j.1552-4604.1997.tb04330.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES